Brief: Imugene Partners with ABL To Advance advance VAXINIA manufacturing
18/10/2022 09:17
Oct 18 (Reuters) - Imugene Ltd IMU.AX :
* ABL AND IMUGENE PARTNER TO ADVANCE ONCOLYTIC VIRUS
CANDIDATE
TOWARDS LATER PHASE CLINICAL TRIALS
Source text for Eikon: ID:nASXbK4whT
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement